Xiangyu(Gigi) Ge
@xiangyuge.bsky.social
Graduate Student at Department of Pathology, Yale University.
Reposted by Xiangyu(Gigi) Ge
1/🚨 New preprint out!🚨
We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance.
🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator.
📄 www.biorxiv.org/content/10.1...
We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance.
🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator.
📄 www.biorxiv.org/content/10.1...
Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition
Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle....
www.biorxiv.org
June 25, 2025 at 7:32 PM
1/🚨 New preprint out!🚨
We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance.
🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator.
📄 www.biorxiv.org/content/10.1...
We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance.
🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator.
📄 www.biorxiv.org/content/10.1...